Details

Autor(en) / Beteiligte

• Levin, Myron J
• Moscicki, Anna-Barbara
• Song, Lin-Ye
• Fenton, Terrence
• Meyer, 3rd, William A
• Read, Jennifer S
• Handelsman, Edward L
• Nowak, Barbara
• Sattler, Carlos A
• Saah, Alfred
• Radley, David R
• Esser, Mark T
• Weinberg, Adriana

Titel

Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old

Ist Teil von

• Journal of acquired immune deficiency syndromes (1999), 2010-10, Vol.55 (2), p.197

Ort / Verlag

United States

Erscheinungsjahr

2010

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Quadrivalent human papillomavirus vaccine (QHPV) is > 95% effective in preventing infection with vaccine-type human papillomavirus. The safety and immunogenicity of QHPV are unknown in HIV-infected children. HIV-infected children (N = 126)-age > 7 to < 12 years, with a CD4% ≥ 15-and on stable antiretroviral therapy if CD4% was < 25-were blindly assigned to receive a dose of QHPV or placebo (3:1 ratio) at 0, 8, and 24 weeks. Adverse events were evaluated after each dose. Serum antibody against QHPV antigens was measured by a competitive Luminex immunoassay 1 month after the third QHPV dose. The safety profile of QHPV was similar in the 2 study arms and to that previously reported for QHPV recipients. QHPV did not alter the CD4% or plasma HIV RNA. Seroconversion to all 4 antigens occurred in > 96% of QHPV recipients and in no placebo recipients. Geometric mean titer was > 27 to 262 times greater than the seropositivity cutoff value, depending on the antigen, but was 30%-50% lower against types 6 and 18 than those of age-similar historical controls. QHPV was safe and immunogenic in this cohort of HIV-infected children. Efficacy trials are warranted.